Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Brilaroxazine (RP 5063) in Patients with Idiopathic-Pulmonary-Fibrosis (IPF)

Trial Profile

A Phase II Trial of Brilaroxazine (RP 5063) in Patients with Idiopathic-Pulmonary-Fibrosis (IPF)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilaroxazine (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors Reviva Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2019 According to a Reviva Pharmaceuticals media release, the FDA has reviewed brilaroxazine IND enabling preclinical data, and clinical phase 1 study results and this phase 2 study plan for IPF. The FDA addressed the companys questions and provided guidance on the brilaroxazine clinical development plan for IPF.The company look forward to initiating this trial for IPF soon.
    • 03 Jun 2019 According to a Reviva Pharmaceuticals media release, the company has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) for its drug candidate brilaroxazine, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF).
    • 11 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top